

7. Philippe, O., Rio, M., Carioux, A., Plaza, J.M., Guigue, P., Molinari, F., Boddaert, N., Bole-Feysot, C., Nitschke, P., Smahi, A., et al. (2009). Combination of linkage mapping and microarray-expression analysis identifies NF-kappaB signaling defect as a cause of autosomal-recessive mental retardation. *Am. J. Hum. Genet.* *85*, 903–908.
8. Mochida, G.H., Mahajnah, M., Hill, A.D., Basel-Vanagaite, L., Gleason, D., Hill, R.S., Bodell, A., Crosier, M., Straussberg, R., and Walsh, C.A. (2009). A truncating mutation of TRAPPC9 is associated with autosomal-recessive intellectual disability and postnatal microcephaly. *Am. J. Hum. Genet.* *85*, 897–902.
9. Mir, A., Kaufman, L., Noor, A., Motazacker, M.M., Jamil, T., Azam, M., Kahrizi, K., Rafiq, M.A., Weksberg, R., Nasr, T., et al. (2009). Identification of mutations in TRAPPC9, which encodes the NIK- and IKK-beta-binding protein, in nonsyndromic autosomal-recessive mental retardation. *Am. J. Hum. Genet.* *85*, 909–915.
10. Fusco, F., Bardaro, T., Fimiani, G., Mercadante, V., Miano, M.G., Falco, G., Israël, A., Courtois, G., D'Urso, M., and Ursini, M.V. (2004). Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation. *Hum. Mol. Genet.* *13*, 1763–1773.
11. Hadj-Rabia, S., Froidevaux, D., Bodak, N., Hamel-Teillac, D., Smahi, A., Touil, Y., Fraitag, S., de Prost, Y., and Bodemer, C. (2003). Clinical study of 40 cases of incontinentia pigmenti. *Arch. Dermatol.* *139*, 1163–1170.
12. Smahi, A., Courtois, G., Vabres, P., Yamaoka, S., Heuertz, S., Munnich, A., Israël, A., Heiss, N.S., Klauck, S.M., Kioschis, P., et al. The International Incontinentia Pigmenti (IP) Consortium. (2000). Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. *Nature* *405*, 466–472.
13. Sebban-Benin, H., Pescatore, A., Fusco, F., Pascuale, V., Gautheron, J., Yamaoka, S., Moncla, A., Ursini, M.V., and Courtois, G. (2007). Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. *Hum. Mol. Genet.* *16*, 2805–2815.
14. Ropers, H.H., and Hamel, B.C. (2005). X-linked mental retardation. *Nat. Rev. Genet.* *6*, 46–57.
15. Aradhya, S., Bardaro, T., Galgóczy, P., Yamagata, T., Esposito, T., Patlan, H., Ciccodicola, A., Munnich, A., Kenwrick, S., Platzer, M., et al. (2001). Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes. *Hum. Mol. Genet.* *10*, 2557–2567.
16. Fusco, F., Paciolla, M., Pescatore, A., Lioi, M.B., Ayuso, C., Faravelli, E., Gentile, M., Zollino, M., D'Urso, M., Miano, M.G., and Ursini, M.V. (2009). Microdeletion/duplication at the Xq28 IP locus causes a de novo IKBKG/NEMO/IKKgamma exon4_10 deletion in families with Incontinentia Pigmenti. *Hum. Mutat.* *30*, 1284–1291.
17. Nelson, D.L. (2006). NEMO, NFkappaB signaling and incontinentia pigmenti. *Curr. Opin. Genet. Dev.* *16*, 282–288.
18. Wong, E.T., and Tergaonkar, V. (2009). Roles of NF-kappaB in health and disease: Mechanisms and therapeutic potential. *Clin. Sci. (Lond.)* *116*, 451–465.

DOI 10.1016/j.ajhg.2010.02.026. ©2010 by The American Society of Human Genetics. All rights reserved.

Response to Fusco et al.

To the Editor: The authors' comments consist of two parts, to which we will reply separately.

1) The authors state that next to *GDII*, overexpression of other genes present within the recurrent aberration should be taken into account as well to explain the MR phenotype in our families. In particular, the *IKBKG* gene is a candidate because mutations have been implicated in IP, often associated with neurological abnormalities, and because the NF-κB pathway has been linked to MR. We completely agree with a prominent role for the *IKBKG* gene and its pathway in neurological disorders and we have taken this gene seriously into account for a role in the MR phenotype of our families. However, we identified a 190 kb duplication, which overlaps our recurrent aberration, in a female patient as well as her normal father. This finding is described on page 812 of our paper¹ and the position of this polymorphic duplication is illustrated in Figure 2 (horizontal striped bar). This benign copy number variant includes, among others, *IKBKG*, which demonstrates that at least a duplication of this gene does not cause a pathological condition. Because *IKBKG* is duplicated in affected males of our family 4, we excluded it as a candidate gene. We do mention that we still have to be careful with this "rejection." We agree, however, that in the sentence on

page 819 "Moreover, the role of other genes within the aberration, such as *UBL4A* and *FAM3A*, cannot be excluded even though the apparent 190 kb copy-number polymorphism identified in a normal male individual seems to exclude a contribution of a double dosage of both genes in family 4," the *IKBKG* gene should have been included as well. Of the remaining genes in the nonoverlapping aberrant region, we did check brain expression for all genes. For those with the highest expression (*FLNA*, *RPL10*, *ATP6AP1*, and *GDII*), we checked their expression levels in patient-derived cell lines. So we did not focus on *GDII* alone but proposed this gene as the most likely candidate gene, which is clearly discussed.

2) The authors would have liked us to put more emphasis on the recombination events that occur between the two oppositely oriented LCRs, L1 and L2, and the consequences these might have on the *IKBKG* gene. In our study, the aim was not to describe the NAHR events that occur between LCR partners (K1 and K2, or L1 and L2). We clearly point to the occurrence of recombination events (see page 816 "... multiple possible NAHR-driven inversion events that could have taken place between the subunits of each set") that probably resulted in homogeneity of the entire LCR. Because *IKBKG* was not regarded as a candidate dosage-sensitive gene for the MR phenotype, and because our male patients as well as their carrier mothers do not show characteristic features of IP, we did not further investigate the *IKBKG*

copy number, which, however, can be deduced from the oligo-array data (GEO accession numbers GPL9083 and GSE17813). Finally, in the paper of Fusco et al.,² the breakpoint of the *MER67B* duplication could have been cloned because of their correct assumption that the *MER67* repeat could have been involved. Moreover, the breakpoint could easily be identified because of a divergent sequence from the reference sequence resulting from the duplication. The reason why we were unable to clone their breakpoints (present somewhere within the LCRs) is because of the >99% sequence identity, their homogeneity, and because in our case we don't have any handle where to look within the 35-kb-large LCR. Moreover, we always expect to find homogeneous reference sequences, which preclude detecting the breakpoints.

Guy Froyen^{1,2,*}

¹Human Genome Laboratory, Department for Molecular and Developmental Genetics, VIB, B-3000 Leuven,

Belgium; ²Human Genome Laboratory, Center for Human Genetics, K.U. Leuven, B-3000 Leuven, Belgium

*Correspondence: guy.froyen@med.kuleuven.be

References

1. Vandewalle, J., Van Esch, H., Govaerts, K., Verbeeck, J., Zweier, C., Madrigal, I., Mila, M., Pijkels, E., Fernandez, I., Kohlhase, J., et al. (2009). Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination. *Am. J. Hum. Genet.* *85*, 809–822.
2. Fusco, F., Paciolla, M., Pescatore, A., Lioi, M.B., Ayuso, C., Faravelli, F., Gentile, M., Zollino, M., D'Urso, M., Miano, M.G., et al. (2009). Microdeletion/duplication at the Xq28 IP locus causes a de novo IKBKG/NEMO/IKKgamma exon4_10 deletion in families with Incontinentia Pigmenti. *Hum. Mutat.* *30*, 1284–1291.

DOI 10.1016/j.ajhg.2010.02.026. ©2010 by The American Society of Human Genetics. All rights reserved.